WO1997022347A1 - Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. - Google Patents
Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. Download PDFInfo
- Publication number
- WO1997022347A1 WO1997022347A1 PCT/NL1996/000488 NL9600488W WO9722347A1 WO 1997022347 A1 WO1997022347 A1 WO 1997022347A1 NL 9600488 W NL9600488 W NL 9600488W WO 9722347 A1 WO9722347 A1 WO 9722347A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- esterase inhibitor
- inhibition
- complement
- dxs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- Txtle Potentiatxon of complement and coaqulatxon inhibitory properties of Cl-inhibitor
- Inflammatory reactions occur in the course of numerous human and animal diseases and are mediated by an array of so-called inflammatory mediators.
- the plasma cascade systems each consist of a series of plasma proteins, most of which are synthesized by the liver and circulate in blood as inactive precursors, also called factors.
- Activation of the first factor of a system comprises conversion by limited proteolysis of the inactive, often single-chain precursor into a cleaved often two-chain active protein. This activated first factor subsequently activates, again by limited proteolysis, a number of inactive second factors, which in turn each activate a number of third factors and so on. This reaction pattern resembles a cascade.
- Cir and Cis are converted from smqle peptide-cham inactive proteins into two-chain active serine proteinases.
- the activated Cl complex then activates the complement factors C4 and C2 , which together form the bi- molecular C4b,2a complex.
- This complex then activates C3, the third component of complement, by cleaving it into the smaller fragment C3a and the larger C3b.
- the C4b,2a complex is hence called a C3-convertase.
- the contact system consists of a set of proteins, which circulate in blood as inactive precursor proteins .
- the system is also known as the contact system of coagulation or the kallikrem-kinin system. Colman R.W. , 1984, J Clin Invest _7_3: 1249; Kaplan A.P. et al., 1987, Blood 2_0: 1; Kozin F. et dl. , 1992, In: Gallin Jl , Goldstein IM,
- the contact system constitutes one of the major plasma cascade systems, and is often regarded as one of the two pathways of clotting, the so-called extrinsic pathway of coagulation being the other.
- Activation of the contact system is controlled by the same protein that also inhibits the classical complement pathway, Cl-in ibitor, and which will be discussed below.
- Cl-in ibitor the classical complement pathway
- several biologically active fragments are formed such as bradykinin, kallikrem and activated factor XII. These fragments may enhance activation and degranulation of neutrophils, increase vasopermeability and decrease vascular tonus.
- Colman R.W. 1984, J Clin Invest 7 : 1249; Kozm F. et al., 1992, In: Gallin Jl , Goldstein IM, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates, New York, Raven Press, p.103.
- each active site of factor XIa is regulated by plasma protease inhibitors including a1-ant ⁇ trypsm, antithrombm III, Cl-mhibitor, and . ⁇ -antiplasmm, each a member of the superfamily of serine protease inhibitors (serpins).
- serpins serine protease inhibitors
- Cl-mhibitor also known as Cl-esterase inhibitor, refers to a protein that is present in blood and is the mam inhibitor of the classical pathway of complement and of the contact system. Cl-inhibitor can inhibit the activated form of the first component of complement and activated factor XII, and it is also a major inhibitor of kallikrem.
- Cl-inhibitor can inhibit the activated form of the first component of complement and activated factor XII, and it is also a major inhibitor of kallikrem.
- Cl-mhibitor regulates the activity of two plasma cascade systems, i.e. the complement and contact systems, that during activation generate biologically active peptides.
- Cl-inhibitor is, therefore, an important regulator of inflammatory reactions.
- Cl-mhibitor is a major inhibitor of activated factor XI. Mei ers J.C.M. et al . , 1988, Biochemistry 2 :
- Cl-inhibitor should therefore also be considered as a coa ⁇ gulation inhibitor. Also tissue-type plasminogen activator and plasm are inhibited to some extent by Cl-inhibitor, although this inhibitor is not the major inhibitor of these proteinases. Harpel P.C. et al., 1975, J Clin Invest 5_5: 149; Booth N.A. et al. , 1987, Blood 6_9: 1600. Cl-mhibitor should therefore also be considered as a (weak) fibrinolytic inhibitor.
- Cl-inhibitor has been purified from plasma at large scale and used for clinical application, particularly m the treatment of he ⁇ ditary angioedema, a disease caused by a genetic deficiency of C1-inhibitor. Furthermore, adimnis- tration of Cl-inhibitor has been claimed to have beneficial effects other diseases as well, such as systemic inflam ⁇ matory responses in mammals [Fong S., 1992, WO 92/22320 (Genentech Inc)], and of complications of severe burns, pancreatitis, bone marrow transplantation, cytokine therapy and the use of extracorporeal circuits [Eisele B.
- serpins may be influenced by glycos- aminoglycans, a heterogeneous group of macromolecular sulphated glycocon ugates linked to a protein core.
- glycos- aminoglycans a heterogeneous group of macromolecular sulphated glycocon ugates linked to a protein core.
- glycosammoglycans in particular heparin, may also potentiate the function of other serpins including Cl- mhibitor:
- heparin In kinetic assays with purified proteins heparin has been shown to potentiate the inhibition of Cis by Cl- mhibitor 15- to 35-fold, whereas the inhibition of activated Cl or Cir is less enhanced.
- Glycosammoglycans may induce a conformational change in the inhibitor, rendering it more active; (II) Glycosammoglycans may work as a template on which inhibitor and target protease may assemble; (III) Glycosammoglycans may neutralize positive charges either on the inhibitor or on the protease or both, thereby allowing a more easy inter ⁇ action. Evans D.L. et al., 1992, Biochemistry 31 : 12629; Bode W. et al., 1994, Fibrinolysis 8: 161; Potempa J. et al., 1994, J Biol Chem 269: 15957. Which one of these mechanism(s) applies to the observed glycosaminoglycan- induced enhancement of Cl-inhibitor function remains to be shown in further studies.
- Cl-inhibitor a major inhibitor of various complement, clotting, contact system and fibrinolytic proteases
- a semisynthetic polyanionic compound the sulphated polysaccharide dextran sulphate
- Cl-inhibitor selectively potentiated up to over 100-fold regarding its complement and clotting inhibitory properties. Therefore, the present invention contemplates a pharmaceutical composition containing Cl-inhibitor with selectively enhanced function, that can be used prophylactically or therapeutically to inhibit activation of complement and/or coagulation in vivo.
- the pharmaceutical composition comprises Cl-mhibitor and dextran sulphate species.
- Factor XIa (final concentration 6 nmol/1) was incubated at 37°C with different concentrations of Cl-inhibitor in 0.1 mol/1 Tris-HCl, pH 7.4, 0.14 mol/1 NaCl, 0.1 . Tw. At various times, aliquots were removed and assayed for residual amidolytic activity of factor XIa. (Panel A)
- Results are expressed as the potentiation factor of the inhibition of factor XIa by Cl-mhibitor in the presence of varying amounts of DXS MW 500,000, DXS MW 5,000, heparin, heparan sulfate or dermatan sulfate, compared with the inhibition rate in the absence of glycosammoglycans or DXS.
- Figure 4 Pseudo first-order rate constants of factor XIa inhibition by Cl-mhibitor in the presence of glycos ⁇ ammoglycans or DXS.
- Cis at a final concentration of 3 nmol/1 was incubated with Cl- mhibitor (final concentration 15 nmol/1) and various glycosammoglycans (each tested at 10 ng/ml) in phosphate buffered saline (PBS)-0.05 ° T ., containing the chromogenic substrate S2314 at a final concentration of 0.8 mmol/l at 37 C
- PBS phosphate buffered saline
- Citrated (10 mmol/l, final concentration) blood was recalci ⁇ fied by adding 10 mM CaCl (final concentration). After 15 mm at 37°C a clot had formed, which was removed by centrifugation for 10 mm at 2,000 x g at 4°C One vol of recalcified plasma was then incubated with one vol veronal buffered saline containing aggregated human IgG at a o concentration of 5 mg/ml for 20 min at 37 C Complement activation durmg this incubation was then measured by assessing the generation of Cls-Cl-inhibitor complexes, C4 and C3 activation products (C4b/C4b ⁇ /C4c and C3b/C3b ⁇ /C3c, respectively).
- Figure 10 Inhibi ion by heparin of complement activation in recalcified plasma by aggregated human IgG. The experiment was performed similarly as that described in Figure 8, except that heparin was used.
- the kernel of the present invention is the realization that Cl-inhibitor, a major inhibitor of complement, clotting, contact system and fibrinolytic proteases in plasma can be modified regarding its inhibitory spectrum by the semisynthetic compound dextran sulphate (DXS): the inhibitory properties of Cl-inhibitor towards complement and coagulation systems are potentiated up to over 100-fold, whereas those towards contact and fibrinolytic systems are not affected. Virtually every method to modify the inhibi ⁇ tory function of Cl-inhibitor by DXS is intended to come into the scope of this invention. Potentiating effects of glycosammoglycans on the inhibition of Cis have been des- cribed previously (see section "Background of invention").
- glycosammoglycans are obtained from animal sources and to a varying extent also potentiate antithrombm III and heparin cofactor II. Low doses of these glycosamino- glycans are used in a clinical setting to treat thrombo- embolic diseases. To obtain inhibition of complement in patients, doses of heparin of at least one order higher are needed, which have the unacceptable risk of bleeding.
- DXS has stronger enhancing effects on the inhibition of factor XIa and Cis than any glycosammoglycan, as is illustrated below; b) only the larger forms of DXS may have some stimulating effects on antithrombm III and treatment with the low MW forms of this compound, therefore, does not have the risk of bleeding tendency; and c) DXS is a semisynthetic compound that can be produced in large quantities, whereas glycosammoglycans such as heparin are purified from animals.
- the present mvention describes the effects of DXS on the inhibition of target proteases factor XIa, factor Xlla, kallikrem and Cis by Cl- hibitor in purified systems. Results obtained with glycosammo ⁇ glycans are also given for comparison.
- the second section describes the effects of DXS on complement activation in plasma. The effects of heparin and N-acetyl-heparm, glycos ⁇ ammoglycans sometimes used as complement inhibitors, are also given for comparison.
- the third section describes the application of DXS in therapeutical compositions containing Cl-inhibitor.
- Hexadimethrme bromide (Polybrene) was from Janssen Chimica, Beerse, Belgium; Tween-20 (Tw) from J.T. Baker Chemical, Phillipsburg, N .
- the chromogenic substrates Glu-Pro-Arg-p- nitroanilide (S-2366; factor XIa substrate) and H-D-Pro-Phe- Arg-p-nitroanilide (S-2302; factor Xlla and kallikrem substrate) were from Chromogenix, M ⁇ lndal, Sweden; H-D-Val- Ser-Arg-p-nitroanilide (S-2314; Cis substrate) from Kabi Diagnostica (Stockholm, Sweden) .
- Purified human factor XIa was obtained from Kordia Laboratory Supplies, Leiden, The Netherlands, and was stored at -70°C in 0.1 mol/1 Tris-HCl , pH 7.4, 0.14 mol/1 NaCl, 0.1° (wt/vol) Tw. This preparation was made by incubating factor XI with factor Xlla, after which factor Xlla was removed by absorption onto a corn trypsin inhibitor column. Factor XIa preparation migrated as a smgle band at 160 kD on non-reducing, and as two bands at 50 and 30 kD, respectively, on reducing SDS/10-15° (wt/vol )-polyacrylamide gel electrophoresis.
- Amidolytic activity of factor XIa was determined in wells of microtiterplates (Greiner GmbH, Frickenhausen, Germany) by using the chromogenic substrate S-2366 at a final concentration of 0.4 mmol/l in a buffer containing 0.1 mol/1 Tris-HCl, pH 7.4, 0.14 mol/1 NaCl, and 0.1 .
- Tw total volume of 200 ⁇ l.
- the initial change in o absorbance at 405 nm ( ⁇ A) was measured at 37 C using a Titertek twinreader (Flow Laboratories, Irvine, UK).
- Factor XIa and inhibitors were incubated in the presence or absence of glycosaminoglycans or DXS in 0.5 ml polypropylene tubes at 37°C with 0.1 mol/I Tris-HCl, pH 7.4, 0.14 mol/1 NaCl, 0.1 % (wt/vol) Tw as a buffer. Before incubation the various components of the mixtures were prewarmed at 37°C for 5 min. After addition of prewarmed factor XIa (final concentrations 3 to 8 nmol/1) to the reaction mixtures, 10 ⁇ l aliquots were removed at various times and residual amidolytic activity of factor XIa was assessed by diluting in 190 ⁇ l buffer and substrate as described above.
- the observed _A/min which was constant during the time of measurement, was converted to percentage of maximum activity by comparison with the _A/m ⁇ n of the sample containing factor XIa and glycosaminoglycan but no protease inhibitor.
- the kinetics of the inhibition were studied under pseudo first-order conditions with the inhibitors in 13 to 210-fold molar excess over factor XIa.
- Inactivation of factor XIa by Cl-inhibitor indeed appeared to follow first-order kinetics under pseudo first-order conditions, as was concluded from the straight lines obtained when the natural logarithm of residual factor XIa amidolytic activity was plotted against time (Fig. 2A) .
- DXS effects of DXS on the inhibition of complement by Cl-inhibitor in serum may be tested by adding DXS to fresh o human serum, followed by incubation at 37 C of the mixture with complement activators such as aggregated IgG, cobra venom factor, E.coli bacteria or zymosan.
- complement activators such as aggregated IgG, cobra venom factor, E.coli bacteria or zymosan.
- complement activation products such as C3a, C4a, C5a, C3b/bi/c, C4b/bi/c or C5b-C9.
- Assays for these complement activation products are well known in the art and can be obtained commercially. The preferred assays are those described byhack CE. et al., 1988, J Immunol Meth 108: 77;
- DXS MW 500,000 as well as DXS MW 5,000 both significantly inhibited complement activation in serum by aggregated IgG: Both DXS species at a concentration of about 100-200 ⁇ g/ml nearly completely inhibited the generation of activated C4 and C3 in serum by the classical pathway activator aggregated IgG. in addition, DXS MW 500,000, but not DXS MW 5,000, also inhibited the generation of Cls-Cl-inhibitor complexes, probably reflecting a direct effect of DXS MW 500,000 on the binding of Clq to aggregated IgG. The effects of heparin and N- acetyl-heparin were explored in similar experiments.
- heparin inhibited complement activation in serum by aggregated IgG similarly as DXS MW 5,000.
- N-acetyl-heparin appeared to be a weaker complement inhibitor than heparin or DXS (Fig. 10). Effects of this heparin-species with reduced anticoagulant properties on the generation of activated C3 were hardly observed, whereas inhibition of C4 activation was not complete unless concentrations of 1 mg/ml were tested.
- Cl-inhibitor is prepared from human plasma, depleted of vitamin K-dependent coagulation factors, according to a procedure which involves the following purification steps: 1) the starting plasma is 1 to 10 diluted with sterile destilled water; 2) the diluted plasma is incubated with DEAE-Sephadex A50 (Pharmacia Fine Chemicals, Uppsala, Sweden) at a concentration of 2 g/kg, for 60 minutes at 8-10°C; 3) the DEAE-Sephadex is collected and washed with 150 mM sodium chloride, pH 7.0, and eluted with 10 mM trisodium citrate, 2 M sodium chloride, pH 7.0; 4) ammonium sulphate is added to the eluate to yield a final concentration of 50%, v/v; 5) after centrifugation at 13,000 rpm, ammonium sulphate is added to the supernatant to yield a final concentration of 65%, v/v; 6) the precipitate is collected by centr
- Cl-inhibitor is mixed with DXS (for example, 100 ⁇ g per Unit of Cl-inhibitor), incubated for one hour; and then adminis ⁇ tered by intravenous injection.
- DXS for example, 100 ⁇ g per Unit of Cl-inhibitor
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9522672A JP2000507204A (en) | 1995-12-18 | 1996-12-18 | Enhanced complement and blood clotting inhibitory properties of C1-inhibitors |
AU10425/97A AU1042597A (en) | 1995-12-18 | 1996-12-18 | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
EP96941227A EP0868191A1 (en) | 1995-12-18 | 1996-12-18 | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
CA 2239787 CA2239787A1 (en) | 1995-12-18 | 1996-12-18 | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95203537.6 | 1995-12-18 | ||
EP95203537 | 1995-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997022347A1 true WO1997022347A1 (en) | 1997-06-26 |
Family
ID=8220969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL1996/000488 WO1997022347A1 (en) | 1995-12-18 | 1996-12-18 | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0868191A1 (en) |
JP (1) | JP2000507204A (en) |
AU (1) | AU1042597A (en) |
WO (1) | WO1997022347A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035802A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
WO2015054569A1 (en) * | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
US9616111B2 (en) | 2013-03-15 | 2017-04-11 | Shire Viropharma Incorporated | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency |
US10478451B2 (en) | 2015-07-30 | 2019-11-19 | Tx Medic Ab | Use of dextran sulfate |
WO2021211044A1 (en) * | 2020-04-15 | 2021-10-21 | Tx Medic Ab | Treatment of sepsis and hypercytokinemia |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988005301A1 (en) * | 1987-01-23 | 1988-07-28 | The Australian National University | Sulphated polysaccharides having anti-metastatatic and/or anti-inflammatory activity |
EP0276370A2 (en) * | 1986-10-09 | 1988-08-03 | Knoll Ag | Use of lower molecular-weight dextran sulfates in the treatment of arteriosclerosis |
EP0293826A2 (en) * | 1987-06-02 | 1988-12-07 | Stichting REGA V.Z.W. | Therapeutic and prophylactic application of sulfated polysaccharides against AIDS |
WO1991005566A1 (en) * | 1989-10-16 | 1991-05-02 | Invitron Corporation | Protease nexin i/dextran sulfate anticoagulant |
EP0473564A1 (en) * | 1990-08-27 | 1992-03-04 | Monsanto Company | Anticoagulant combination of laci and sulfated polysaccharides |
WO1992022320A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
DE4227762A1 (en) * | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Use of a kallikrein inhibitor for the manufacture of a medicament for the prophylaxis and therapy of certain diseases |
-
1996
- 1996-12-18 AU AU10425/97A patent/AU1042597A/en not_active Abandoned
- 1996-12-18 JP JP9522672A patent/JP2000507204A/en active Pending
- 1996-12-18 WO PCT/NL1996/000488 patent/WO1997022347A1/en not_active Application Discontinuation
- 1996-12-18 EP EP96941227A patent/EP0868191A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0276370A2 (en) * | 1986-10-09 | 1988-08-03 | Knoll Ag | Use of lower molecular-weight dextran sulfates in the treatment of arteriosclerosis |
WO1988005301A1 (en) * | 1987-01-23 | 1988-07-28 | The Australian National University | Sulphated polysaccharides having anti-metastatatic and/or anti-inflammatory activity |
EP0293826A2 (en) * | 1987-06-02 | 1988-12-07 | Stichting REGA V.Z.W. | Therapeutic and prophylactic application of sulfated polysaccharides against AIDS |
WO1991005566A1 (en) * | 1989-10-16 | 1991-05-02 | Invitron Corporation | Protease nexin i/dextran sulfate anticoagulant |
EP0473564A1 (en) * | 1990-08-27 | 1992-03-04 | Monsanto Company | Anticoagulant combination of laci and sulfated polysaccharides |
WO1992022320A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
DE4227762A1 (en) * | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Use of a kallikrein inhibitor for the manufacture of a medicament for the prophylaxis and therapy of certain diseases |
Non-Patent Citations (1)
Title |
---|
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; M. SAMUEL ET AL, XP002006375 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035802A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
US9616111B2 (en) | 2013-03-15 | 2017-04-11 | Shire Viropharma Incorporated | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency |
US10080788B2 (en) | 2013-03-15 | 2018-09-25 | Shire Viropharma Incorporated | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency |
US10105423B2 (en) | 2013-03-15 | 2018-10-23 | Shire Viropharma Incorporated | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency |
US10130690B2 (en) | 2013-03-15 | 2018-11-20 | Shire Viropharma Incorporated | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency |
US10201595B2 (en) | 2013-03-15 | 2019-02-12 | Shire Viropharma Incorporated | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency |
US11364288B2 (en) | 2013-03-15 | 2022-06-21 | Viropharma Biologics Llc | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency |
US11534482B2 (en) | 2013-03-15 | 2022-12-27 | Viropharma Biologics Llc | C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency |
WO2015054569A1 (en) * | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
US10478451B2 (en) | 2015-07-30 | 2019-11-19 | Tx Medic Ab | Use of dextran sulfate |
WO2021211044A1 (en) * | 2020-04-15 | 2021-10-21 | Tx Medic Ab | Treatment of sepsis and hypercytokinemia |
Also Published As
Publication number | Publication date |
---|---|
AU1042597A (en) | 1997-07-14 |
EP0868191A1 (en) | 1998-10-07 |
JP2000507204A (en) | 2000-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wuillemin et al. | Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. | |
EP0497756B1 (en) | Antithrombotic composition | |
Day et al. | Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit | |
Holm et al. | Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin | |
De Zwaan et al. | Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction | |
Hara et al. | DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats | |
Levi | Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient | |
Wun | Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides | |
EP0473564B1 (en) | Anticoagulant combination of laci and sulfated polysaccharides | |
Turpie | Fondaparinux: a factor Xa inhibitor for antithrombotic therapy | |
Cadroy et al. | Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates | |
RU2153506C2 (en) | Dermatan sulfate or its salt, antithrombotic agents, method of prophylaxis and treatment of thrombosis, method of prophylaxis or treatment of disseminated intravascular coagulation syndrome, method of myocardium infarction treatment | |
EP0868191A1 (en) | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. | |
HU221323B1 (en) | Synergetic anti-coagulant preparatives containing epi protein and mucopolysaccharide and process for producing them | |
Bendetowicz et al. | On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin (enoxaparin) | |
Okamura et al. | Treatment of disseminated intravascular coagulation and its prodromal stage with gabaxate mesilate (FOY): a multi-center trial | |
Olson et al. | Mechanism of action of heparin and heparin-like antithrombotics | |
Kaiser et al. | Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans | |
Andersson et al. | Mechanisms of anticoagulant effects of some sulphated polysaccharides | |
CA2239787A1 (en) | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor | |
Bridey et al. | Recombinant hirudin (HBW 023): Biological data of ten patients with severe venous thrombo‐embolism | |
Kaiser et al. | Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders | |
KR20030069990A (en) | Antithrombotic compositions | |
Jeske | Pharmacologic studies on synthetic analogues of heparin with selective affinity to endogenous serine protease inhibitors | |
Kaiser et al. | A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2239787 Country of ref document: CA Ref country code: JP Ref document number: 1997 522672 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2239787 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996941227 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996941227 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996941227 Country of ref document: EP |